• The US Patent and Trademark Office issued Jaguar Health, Inc. (Nasdaq: JAGX) a new US patent for using crofelemer to treat short bowel syndrome (SBS), bolstering intellectual property protection.
• The new patent supports proof-of-concept studies of crofelemer for SBS and microvillus inclusion disease, with results expected by the end of 2023.
• Crofelemer has been granted Orphan Drug Designation for both SBS and microvillus inclusion disease in the US and Europe.
• Jaguar to host a virtual educational webinar on intestinal failure with leading gastroenterologists and nutrition experts on November 8th from 1:00 PM to 2:30 PM EST; register for the webinar here.

• Unicycive Therapeutics, Inc. (Nasdaq: UNCY) Reached alignment with FDA on requirements to file NDA for lead drug candidate Oxylanthanum Carbonate (OLC) to treat hyperphosphatemia.
• Management expects to initiate a pivotal clinical trial for OLC before the end of 2023, with top-line data in Q2 2024 to support NDA filing.
• The company has over $18 million cash on hand, enough to fund operations into the second half of 2024, including completing a pivotal OLC trial.

• Treasure Global Inc. (Nasdaq: TGL) signed a Memorandum of Understanding with a leading Malaysian healthcare provider UCSI Hospital to promote healthcare tourism and stem cell therapies.
• The partnership will help monetize the ZCITY app user base, with a projected significant increase in monthly gross profit.
• The company will earn commissions on health screenings, enogy product sales, and new stem cell therapy offerings for tourists.

• Kiora Pharmaceuticals, Inc. (Nasdaq: KPRX) will present topline results from Phase 1b ABACUS study of KIO-301 in retinitis pigmentosa at the American Academy Ophthalmology conference on November 4th in San Francisco.
• The study evaluated safety, tolerability, and efficacy in six patients over 28 days, with no reported serious adverse events.
• Efficacy analysis to include changes in visual fields, visual acuity, functional vision, and functional MRI of the visual cortex from baseline.

• AppTech Payments Corp. (Nasdaq: APCX) announced a $3.5 million registered direct offering of common stock and warrants to institutional investors.
• The company also completed acquisition of FinZeo, a software development company for payment and banking solutions.
• The FinZeo acquisition expands capabilities and the addressable market for AppTech's digital Commerse platform.

• Renovaro Biosciences Inc. (NASDAQ: RENB) appointed Avram Miller, co-founder of Intel Capital, to the Board of Directors. Miller brings significant experience in medical science, technology, and business development.
• Two new independent directors, Leni Boeren and Ruud Hendriks, with extensive finance and business expertise, were also added.
• The strengthened board leadership is an important step, as Renovaro works towards combining with AI company GEDiCube to transform cancer care.

• AIM ImmunoTech Inc. (NYSE American: AIM) announced that its abstract was accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 1-5 in San Diego.
• The abstract details the Phase 2 study combining Ampligen, cisplatin, and pembrolizumab in recurrent platinum-sensitive ovarian cancer patients.
• The study aims to evaluate the efficacy and safety of using intraperitoneal chemoimmunotherapy to trigger T-cell response.

• GRI Bio, Inc. (Nasdaq CM: GRI) presented data at the Antifibrotic Drug Development Summit, supporting the approach of using NKT cell modulators to treat inflammatory and fibrotic diseases.
• Lead candidate GRI-0621 was shown to inhibit iNKT cell activity and reduce lung fibrosis in preclinical models when dosed orally daily.
• On track to launch Phase 2a biomarker study of GRI-0621 in idiopathic pulmonary fibrosis patients before the end of 2023.

We hope the above snippets of news help keep you informed about some of our Featured Companies. Unfortunately, we couldn't put all the news from the eight companies highlighted above and, definitely, not enough room in one email to talk about our entire family of 22 Featured Companies. 

If you have any questions about our Featured Companies, upcoming Featured Conferences, or any ways we can work together, please don't hesitate to reach out by email, phone, or LinkedIn. Spontaneous calls are welcome. If I am not in a meeting, the phone is always within arm's reach.

David Shapiro
Chief Executive Officer
B2i Digital, Inc.
212-579-4844 (office)
917-806-4171 (cell)

Feel free to Follow B2i Digital on LinkedIn. Then send me a message. I will be happy to reciprocate and follow your page or profile.

B2i Digital, Inc. provides digital marketing support to the above-mentioned Featured Companies, the Featured Companies hosted on b2idigital.com, and the Featured Conference companies hosted on b2idigital.com. B2i Digital has not independently verified the accuracy of the information contained herein or on b2idigital.com. The content was provided by the Companies or from publicly available sources. B2i Digital, Inc. makes no warranties regarding the accuracy of any information provided. No content contained herein or on b2idigital.com shall be considered an offer to solicit the sale of any security or be considered as an opinion as to its investment suitability. Full disclaimer: https://b2idigital.com/disclaimer.